Compass Pathways’ COMP006 Trial Delivers 3.8-Point MADRS Reduction, Shares Jump 23%
Compass Pathways’ Phase 3 COMP006 trial of 25 mg COMP360 hit its primary endpoint with a mean 3.8-point MADRS reduction versus 1 mg (p<0.001) and 39% of participants achieving ≥25% improvement. Shares rose 23% premarket to $7.15, trading 31% above 12-month performance and nearing 52-week highs.
1. COMP006 Trial Outcomes
Compass Pathways reported that its Phase 3 COMP006 trial of COMP360 in treatment-resistant depression achieved a mean 3.8-point greater reduction in MADRS scores for the 25 mg arm versus 1 mg (p<0.001), with 39% of participants in COMP006 reaching a ≥25% symptom reduction.
2. Safety and Tolerability
COMP360 was generally well-tolerated, with most treatment-emergent adverse events classified as mild or moderate and no new safety signals emerging in the 25 mg cohort, reinforcing the profile observed in the earlier COMP005 trial.
3. Market Reaction
Shares of Compass Pathways jumped 23% in premarket trading to $7.15, reflecting a 31% gain over the past 12 months and positioning the stock closer to its 52-week high, while technical indicators show neutral RSI and MACD below its signal line.
4. Regulatory Path and Analyst Outlook
The company plans to submit an NDA in Q4 2026 for COMP360; analysts maintain a Buy consensus with an average target of $18.15, including RBC at $21, Morgan Stanley at $11 and BTIG at $14, and the stock holds an 8.62% weight in the AdvisorShares Psychedelics ETF.